Matteo Colombo RBC Capital Markets has started Apellis Pharmaceuticals ( NASDAQ: APLS ) off at sector perform citing limited opportunity for Syfovre (pegcetacoplan) in geographic atropathy. The firm has a $25 price target (~9% downside based on Oct. 24 close).
Analyst Lisa Walter said that.
